Eliem Therapeutics
ELYM

$8.65

2.81%

Market Cap: 578M

About: Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).

Employees: 11

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

2% more capital invested

Capital invested by funds: $45.5M [Q4 2023] → $46.2M (+$689K) [Q1 2024]

0.01% more ownership

Funds ownership: 61.13% [Q4 2023] → 61.14% (+0.01%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

9% less funds holding

Funds holding: 23 [Q4 2023] → 21 (-2) [Q1 2024]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ELYM.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ELYM published over the past 30 days

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today.

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investigation seeks to determine whether Eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating the securities laws and causing harm to the company's shareholders.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh encourages Eliem shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Eliem and its board violated the.

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Companies to host webcast today, April 11, 2024 at 8:30 a.m. EDT SEATTLE and CAMBRIDGE, United Kingdom, April 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem”) and Tenet Medicines, Inc. (“Tenet”), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

See News Rankings